Bou Zerdan Maroun, Bidikian Aram H, Alameh Ibrahim, Nakib Clara El, Assi Hazem I
Division of Hematology and Oncology, Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Rare Tumors. 2021 Jul 18;13:20363613211034115. doi: 10.1177/20363613211034115. eCollection 2021.
Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care center in the Middle East and North Africa region. Monitor the effect of Olaratumab on sarcomas when it was used prior to its withdrawal, and compare our findings with the literature. We performed a retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018. Fifteen patients were included in the study. The mean age was 49 with a range of 26-75 years. The median duration of the use of Olaratumab was 21.3 months with a range of 7.3-37 months. The average number of number of cycles received per patient was four. Five patients were deceased. Median PFS was 7.87 months (95% CI 5.28-10.45), and mean OS was 12.26 months (95% CI 8.47-16.05) Median OS was 9.8 months (95% CI 6.07-13.53). Olaratumab has been withdrawn from the market, and it is currently being investigated as part of the phase II ANNOUNCE 2 trial. Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions.
软组织肉瘤仍然是最罕见的恶性肿瘤之一，有许多亚型未被诊断出来。PDGFRα拮抗剂奥拉单抗（Lartruvo）由于III期研究结果令人失望而退出市场。我们分享在中东和北非地区一家三级护理中心使用这种药物的经验。监测奥拉单抗在撤市前使用时对肉瘤的疗效，并将我们的研究结果与文献进行比较。我们对2017年1月1日至2018年12月31日期间在黎巴嫩一家三级护理中心接受至少两个周期奥拉单抗治疗的晚期/转移性软组织肉瘤成年患者进行了回顾性分析。15名患者纳入研究。平均年龄为49岁，范围在26 - 75岁之间。奥拉单抗的中位使用时间为21.3个月，范围在7.3 - 37个月之间。每位患者接受的平均周期数为4个。5名患者死亡。中位无进展生存期为7.87个月（95%置信区间5.28 - 10.45），平均总生存期为12.26个月（95%置信区间8.47 - 16.05），中位总生存期为9.8个月（95%置信区间6.07 - 13.53）。奥拉单抗已退出市场，目前正在作为II期ANNOUNCE 2试验的一部分进行研究。我们在一家三级护理中心的经验显示结果与文献报道相似。软组织肉瘤的免疫原性和异质性对软组织肉瘤的治疗构成挑战，但也允许有多种可能的管理解决方案。
